Emre Baser, Director, Medical Diagnostics at AstraZeneca, shared a post on LinkedIn:
“I am thrilled to be part of the 25th Precision Medicine World Conference (PMWC 2026), taking place March 4–6, at the Santa Clara Convention Center in California, co-hosted by Stanford, UCSF and Yale.
The session ‘Serial ctDNA-Guided Therapy Switching’, is part of the Track 3: Liquid Biopsy – Therapy Guidance and Monitoring Track, March 5th, where I’ll be joining leading experts to discuss how longitudinal ctDNA dynamics can inform earlier, more precise treatment adjustments and resistance detection—helping teams pivot faster to the right therapy and improve patient outcomes.
I look forward to connecting at PMWC26.
Program.”
More posts on OncoDaily.